Apelin, plasmatic osmolality and hypotension in dialyzed patients

Blood Purification

Volumn 33, Issue 4, 2012, Pages 317-323

  Cernaro, Valeria ^a   Lacquaniti, Antonio ^a   Lorenzano, Giuseppina ^a   Loddo, Saverio ^a   Romeo, Adolfo ^a   Donato, Valentina ^a   Lupica, Rosaria ^a   Buemi, Antoine ^a   Buemi, Michele ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Apelin; Arginine vasopressin; Inflammation; Intradialytic hypotension; Plasmatic osmolality

Indexed keywords

APELIN; ARGIPRESSIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; ARTICLE; CHRONIC PYELONEPHRITIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DIABETIC NEPHROPATHY; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LABORATORY TEST; MALE; MEAN ARTERIAL PRESSURE; PLASMA OSMOLALITY; PRIMARY INTERSTITIAL NEPHRITIS; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84862196657     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000337104     Document Type: Article

References (23)

1. den Ouden DT, Meinders AE: Vasopressin: physiology and clinical use in patients with vasodilatory shock: a review. Neth J Med 2005; 63: 4-13.
2. Llorens-Cortès C, Beaudet A: Apelin, a neuropeptide that counteracts vasopressin secretion. Med Sci (Paris) 2005; 21: 741-746.
3. Bodineau L, Hus-Citharel A, Llorens-Cortes C: Contribution of apelin to water balance, blood glucose control, and cardiovascular functions. Ann Endocrinol (Paris) 2010; 71: 249-256.
4. Corvol P: Effect of apelin in cardiovascular system and water metabolism. Therapie 2009; 64: 233-239.
5. Roberts EM, Pope GR, Newson MJ, Landgraf R, Lolait SJ, O'Carroll AM: Stimulus-specific neuroendocrine responses to osmotic challenges in apelin receptor knockout mice. J Neuroendocrinol 2010; 22: 301-308.
6. Shoji T, Tsubakihara Y, Fujii M, Imai E: Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004; 66: 1212-1220.
7. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, Lawrie KW, Hervieu G, Riley G, Bolaky JE, Herrity NC, Murdock P, Darker JG: Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003; 84: 1162-1172.
8. Reaux A, Gallatz K, Palkovits M, Llorens-Cortes C: Distribution of apelin-synthesizing neurons in the adult rat brain. Neuroscience 2002; 113: 653-662.
9. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP: International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev 2010; 62: 331-342.
10. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 20; 251: 471-476.
11. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD, Newby DE: Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 2010; 27; 121: 1818-1827.
12. O'Carroll AM, Selby TL, Palkovits M, Lolait SJ: Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta 2000; 21; 1492: 72-80.
13. Reaux-Le Goazigo A, Morinville A, Burlet A, Llorens-Cortes C, Beaudet A: Dehydrationinduced cross-regulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons. Endocrinology 2004; 145: 4392-4400.
14. Thornton SN: Thirst and hydration: physiology and consequences of dysfunction. Physiol Behav 2010; 26; 100: 15-21.
15. Thompson AM, Oliver JA: Endogenous and exogenous vasopressin during hemodialysis. Semin Dial 2009; 22: 472-475.
16. Rho M, Perazella MA, Parikh CR, Peixoto AJ, Brewster UC: Serum vasopressin response in patients with intradialytic hypotension: a pilot study. Clin J Am Soc Nephrol 2008; 3: 729-735.
17. Shimizu K, Kurosawa T, Sanjo T: Effect of hyperosmolality on vasopressin secretion in intradialytic hypotension: a mechanistic study. Am J Kidney Dis 2008; 52: 294-304.
18. Azizi M, Iturrioz X, Blanchard A, Peyrard S, De Mota N, Chartrel N, Vaudry H, Corvol P, Llorens-Cortes C: Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol 2008; 19: 1015-1024.
19. Llorens-Cortes C, Moos F: Opposite potentiality of hypothalamic coexpressed neuropeptides, apelin and vasopressin in maintaining body-fluid homeostasis. Prog Brain Res 2008; 170: 559-570.
20. Zhang DL, Liao H, Wei YY, Zhang Y, Zhang QD, Wang ZG: Elevation of serum apelin-13 is positively correlated with ADMA in patients on maintenance hemodialysis. Clin Nephrol 2009; 71: 405-412.
21. Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I, Ercin CN, Dogru T, Kilic S, Uckaya G, Yilmaz MI, Erbil MK, Kutlu M: Plasma apelin and ADMA levels in patients with essential hypertension. Clin Exp Hypertens 2010; 32: 179-183.
22. El-Shehaby AM, El-Khatib MM, Battah AA, Roshdy AR: Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients. Scand J Clin Lab Invest 2010; 70: 421-427.
23. Selby NM, McIntyre CW: The acute cardiac effects of dialysis. Semin Dial 2007; 20: 220-228.